BT13 is a short-living compound having lower efficacy than GDNF (for example its activated luciferase in screening assay by maximum 11.6 fold, whereas GDNF—by 50–100 folds (Sidorova et al., 2010), thus, it is unlikely to promote cancers as a result of RET activation. The gene discussed is RET; the disease is cancer.